MetaCap

Imunon (IMNN) vs Silo Pharma (SILO)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Silo Pharma is the larger company by market cap ($3.7 million vs $3.5 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

IMNN-53.03%SILO+18.75%
+37%-10%-57%
Oct 7, 20261 yearNov 20, 2026
IMNN-50.42%SILO+16.33%
+29%-13%-54%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

IMNN versus SILO key metrics
MetricIMNNSILO
Share price$0.5355$1.71
Market cap$3.47M$3.69M
1-day change-5.22%-9.04%
EPS (TTM)$-3.31$-2.26
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$72.10K
Revenue growth (YoY)—0.00%
Net income (latest FY)$-14.50M$-4.23M
Gross margin—38.57%
Operating margin—-5936.95%
Net margin—-5863.50%
52-week high$4.35$10.43
52-week low$0.50$1.10
Distance from 52-week high-87.69%-83.60%
Analyst consensusstrong_buy—
Avg. price target upside+3074.60%—
Average volume150.49K65.47K
Shares outstanding6.49M2.16M
Employees203
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Imunon

IMNN stock →

Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines in the United States. The company's lead clinical program is IMNN-001, a DNA-based immunotherapy that is in a Phase 3 clinical trial for the localized treatment of advanced ovarian cancer, as well as in the IND-enabling phase for colorectal and pancreatic cancers, and in the discovery phase for glioblastoma.

Health Care · Biotechnology: Pharmaceutical Preparations · 20 employees

About Silo Pharma

SILO stock →

Silo Pharma, Inc. operates as a developmental stage biopharmaceutical company.

Health Care · Biotechnology: Pharmaceutical Preparations · 3 employees

IMNN vs SILO FAQ

Which is bigger, Imunon or Silo Pharma?

Silo Pharma (SILO) is larger, with a market capitalization of $3.69M compared with $3.47M for Imunon (IMNN).

Are Imunon and Silo Pharma in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons